{"title":"Association of GIPR gene variant on the risk of type 2 diabetes mellitus: A case-control study","authors":"Shahrzad Manavi Nameghi","doi":"10.1016/j.endmts.2023.100140","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Type 2 diabetes mellitus (T2DM), as a worldwide health challenge, is a multifactorial disease that environmental and genetic factors contribute to its pathogenicity. Gastric Inhibitory Polypeptide Receptor (GIPR) is a G-pro receptor that controls the gut hormones release and insulin secretion. The current study aimed to investigate the role of the <em>GIPR</em> rs1800437 gene variant in T2DM susceptibility.</p></div><div><h3>Material and methods</h3><p>A total of 108 confirmed T2DM patients and 100 normal controls were recruited in the study. The <em>GIPR</em> rs1800437 genotypes were determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) assay.</p></div><div><h3>Results</h3><p>A significant difference was found in genotypes (CC, CG, and GG) frequency of the <em>GIPR</em> rs1800437 variant between T2DM and control groups (P = 0.02). The homozygote CC genotype of the variant significantly decreased the odds ratio (OR) of diabetes mellitus risk, approximately 50 %, in comparison with the heterozygous GC genotype. The frequency of the C allele among cases was considerably lower than controls (P = 0.002, OR = 0.51, CI = 0.33–0.79).</p></div><div><h3>Conclusion</h3><p>The findings of the study show enough evidence that there is a significant association between the rs1800437 <em>GIPR</em> genetic variant and the risk of T2DM.</p></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666396123000171/pdfft?md5=03fb68971ff2d74ce700bdb895b197c9&pid=1-s2.0-S2666396123000171-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine and Metabolic Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666396123000171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Type 2 diabetes mellitus (T2DM), as a worldwide health challenge, is a multifactorial disease that environmental and genetic factors contribute to its pathogenicity. Gastric Inhibitory Polypeptide Receptor (GIPR) is a G-pro receptor that controls the gut hormones release and insulin secretion. The current study aimed to investigate the role of the GIPR rs1800437 gene variant in T2DM susceptibility.
Material and methods
A total of 108 confirmed T2DM patients and 100 normal controls were recruited in the study. The GIPR rs1800437 genotypes were determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) assay.
Results
A significant difference was found in genotypes (CC, CG, and GG) frequency of the GIPR rs1800437 variant between T2DM and control groups (P = 0.02). The homozygote CC genotype of the variant significantly decreased the odds ratio (OR) of diabetes mellitus risk, approximately 50 %, in comparison with the heterozygous GC genotype. The frequency of the C allele among cases was considerably lower than controls (P = 0.002, OR = 0.51, CI = 0.33–0.79).
Conclusion
The findings of the study show enough evidence that there is a significant association between the rs1800437 GIPR genetic variant and the risk of T2DM.